Grant ID RP190208
Awarded On August 21, 2019
Title Dissecting cellular heterogeneity of bulk tumors for prediction of overall survival and responsive patients to immunotherapy
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Computational Biology
Institution/Organization The University of Texas Southwestern Medical Center
Principal Investigator/Program Director Tao Wang
Cancer Sites Kidney and Renal Pelvis
Contracted Amount $900,000*

*Pending contract negotiation

Lay Summary

RCCs affect a wide range of demographics in the U.S. At the time of diagnosis, ~30% of RCC patients already have metastatic disease and ~30% of patients will recur. 5-year survival for patients who recur is smaller than 10%. Although immunotherapy is transforming cancer care, the response rate is only ~25%, and it’s still unclear how to distinguish responsive patients. The stroma/immune cellular components are critical for immunotherapy response and prognosis in RCC patients. Therefore, it is essential to accurately characterize tumor immunity responses in RCC on the genome-wide scale. We propose to first dissect bulk tumor expression into the tumor cell, normal parenchyma, and tumor stroma/...

Read More